Conference Proceedings

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Gilles Salles, Hervé Tilly, Aristeidis Chaidos, Pam McKay, Tycel J Phillips, Sarit E Assouline, Connie Lee Batlevi, Philip Campbell, Vincent Ribrag, Gandhi Laurent Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kaźmierczak, Stephen Opat, John A Radford, Anna Schmitt, Jennifer Whalen, Anthony Hamlett, Beth Kamp, Deyaa Adib Show all

Blood | American Society of Hematology | Published : 2020


Background: Tazemetostat, a first-in-class, oral, enhancer of zeste homolog 2 (EZH2) inhibitor was recently approved by the US Food and Drug Administration in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after demonstrating single-agent, antitumor activity in patients with wild-type (WT) or mutant (MT) EZH2. Progression of disease within 24 months (POD24), exposure to multiple lines of prior therapy, and refractoriness to rituximab therapy have been shown to adversely affect the prognosis of patients receiving second- or third-line regimens for R/R FL, including chemoimmunotherapy. We performed a post hoc exploratory analysis to better understand how these factors impact ..

View full abstract

Citation metrics